89bio (NASDAQ: ETNB)

Akero Therapeutics

This company develops metabolic disease treatments for patients with metabolic dysfunction-associated steatohepatitis and other liver conditions.

Inventiva

This biopharmaceutical company develops oral small molecule therapies for patients with metabolic dysfunction-associated steatohepatitis and other fibrotic or metabolic diseases.

Altimmune

This biopharmaceutical company develops peptide-based therapeutics for patients with obesity and liver diseases, including metabolic dysfunction-associated steatohepatitis and alcohol-associated liver disease.

Cymabay Therapeutics

This biopharmaceutical company develops oral therapies for patients with chronic liver diseases and metabolic disorders including primary biliary cholangitis.

Eternygen

This biopharmaceutical company develops small molecule inhibitors targeting metabolic diseases, such as fatty liver and diabetes, for patients needing novel medical treatments.

AKRO

This company develops injectable medicines to treat patients with serious metabolic diseases, primarily metabolic dysfunction-associated steatohepatitis.

Zealand Pharma

This biotechnology company develops peptide-based medicines for patients with obesity, rare diseases and chronic inflammation through metabolic health research.

Staten Biotechnology

This company develops monoclonal antibody therapies for patients with dyslipidaemia to reduce cardiovascular risk and lower triglyceride levels.